Good afternoon, and welcome to the Hologic Incorporated First Quarter Fiscal 2014 Earnings Conference Call. My name is Matt and I am your operator for today’s call. This conference is being recorded and all lines have been placed on mute. I would now like to introduce Deborah Gordon, Vice President, Investor Relations to begin the call.

Thank you, Matt. Good afternoon and thank you for joining us for Hologic’s first quarter fiscal 2014 earnings call. The replay of this call will be archived on our website through Friday, February 21 and a copy of our press release discussing our first quarter results, as well as our second quarter and fiscal 2014 guidance, is available in the Overview section of the Investor Relations section of our website. Also in that section is the PowerPoint presentation related to the comments that will be made during today’s opening remarks. Before we begin, I would like to inform you that certain statements made by Hologic during the course of this call may constitute forward-looking statements. These statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from any future results implied by such statements. Such factors include those referenced in our Safe Harbor statement and our first quarter 2014 earnings release and in the company’s filings with the SEC. Also during this call, we will be discussing certain financial measures not prepared in accordance with generally accepted accounting principles, or GAAP. A reconciliation of these non-GAAP financial measures to the related GAAP financial measures can also be found in our first quarter earnings release, including the financial tables in the release. Please note, today’s call will consist of opening remarks from management followed by a Q&A session. Please feel free to go back into queue and if time permits, we will be more than happy to take your follow-up questions at that time. With that, I would now like to turn the call over to Stephen MacMillan, President and Chief Executive Officer.

Thank you, Deb and thank you all for joining us today. I am pleased to be here this evening for my first Hologic earnings call. Before turning to our quarterly results, I would like to briefly highlight my initial experiences and outline an early roadmap for our future. In my first two months, I have been meeting with many of our team members to acquaint myself with the business and better understand the opportunities that lie ahead as well as the near-term challenges we face. My initial observations are simple. Like many businesses, we have our share of challenges, but most importantly, we have a great set of businesses and people. It is now time to reorient ourselves from an acquisition led model to one focused on organic growth via a stepped up operational focus and a clear commitment to paying down our debt. I joined the company because of its unparalleled portfolio of assets. As the dynamics of healthcare continue to evolve, the sweet spot will be products and technologies that improve patient care, make delivery of care more efficient and reduce healthcare costs. We have tremendous opportunities as our market-leading technologies are aligned with these important industry trends. While so much emphasis in our healthcare system is placed on treatment, we believe there is a huge opportunity to improve care and reduce costs through better diagnosis and we can play a role here. As an example, our 3D tomo franchise can dramatically improve cancer detection rates while also significantly reducing the need for unnecessary callbacks, a true win for patients and the healthcare system. As you know, prior to my joining the company, a strategic review process was already underway. I have become involved in that process, building on a lot of the work that has been done.…

Thank you, Steve. Unless otherwise noted, all of my commentary regarding changes will be on a year-over-year basis. First quarter revenues were $612 million, a decrease of 3% compared to reported revenues of $631 million and 5% compared to non-GAAP revenues of $644 million, which reflect the addition of $13.3 million primarily related to a purchase accounting adjustment recorded in the prior year. Q1 revenues last year also included $12.6 million from LIFECODES, a business we divested in March 2013. Diagnostics revenues declined 6.6% to $286 million on a reported basis and 10.5% on a non-GAAP basis when factoring in the $13.3 million adjustment primarily related to purchase accounting. As expected, the decrease is primarily attributable to the absence of sales from the divested LIFECODES business as well as declines in our ThinPrep and blood screening businesses, which were consistent with the fiscal 2014 headwinds we described on our last earnings call. As I mentioned last quarter, we will no longer refer to Legacy Hologic or Gen-Probe results, now that we are a path to one year anniversary of the acquisitions closed. However, in order to provide more visibility into our diagnostics business, we will begin discussing results in three categories: molecular, cytology and perinatal and blood screening. First, cytology and perinatal revenues declined 11% in Q1, which was in line with the expectations we have set forth last quarter largely attributable to the anticipated volume declines in our ThinPrep business as a result of expanded screening intervals in the U.S. as well as lower average selling prices internationally. Blood screening revenues declined 14% on a non-GAAP basis. The decrease was driven largely by an expected decline in assay sales related to higher than usual West Nile virus orders in the first quarter of the prior year. And in molecular,…

Thanks Glenn and before we take questions, I just want to reiterate how excited I am to be here at Hologic. While there is no denying we face some near-term challenges, looking beyond them I see a bright future. We have unique platforms and products that will continue to deliver cutting edge solutions that answer the unmet needs of diverse markets. I am confident we are implementing the right strategies to create shareholder value and position Hologic for growth and success. In the months ahead we look forward to updating you on our progress and providing additional details on our vision for our future. And with that operator please open the call up to questions.

(Operator Instructions) At this time we will take a question from Tycho Peterson with JPMorgan. Please go ahead.

Hi, thanks for taking my question. You guys in the slides kind of removed some of the segment highlights and so just wondering if you can touch on margins for the segments, if there is anything in any of the divisions that was off trend from the prior couple of quarters. And then as a follow-up, Steve you talked a little about returning to organic growth and your predecessors have talked about return to organic growth in fiscal 2015, so I am just wondering if you are comfortable with the timelines that were previously laid out?

Sure, I will let Glenn handle the margins and I will…

Yes, Tycho let me start with the gross margins if I could. We won’t be breaking out that level of detail going forward for the segments on the individual gross margins, but I will say we had a very nice quarter for gross margins in Q1, a little bit better than 63% and it is because we saw its strength on the Breast Health side. We’re getting nice average on prices, nice product mix to the 3D tomo systems and we’re seeing very nice service margin as the service group that we have is very profitable especially in light of kind of a delay in some hiring that we have had on the service side. But we won’t be able to provide that in the same level of detail as in the past, Tycho.

And Tycho on the growth front clearly our plan would be to generate some level of growth in 2015. This part of me says at the highest level 2014 is about stopping the declines, 2015 shoring up that base. But I feel pretty good that I think even as the course of 2014 plays out, we will hopefully show less of declines and even flatten this business out certainly before the year is out and be able to start to get towards growth for next year. And it’s really driven by my confidence in especially the U.S. Molecular Diagnostics business and our U.S. Breast Health businesses. And by the way those two and frankly to drove in even that the surgical business that will grow, just the U.S. for those three businesses accounts for about 70% of our revenue. And I think all three of those can show sequential improvements through the year, sequentially obviously they were down in this quarter for two out of three Breast Health was up but basically the diagnostics business should be less down towards moving towards positive, the surgical business should be moving towards positive, Breast Health of anything will probably accelerate a little bit through the year. And I think really hopefully have us accelerating through this year and setting the platform for growth next year.

Thank you.

Great. Thank you.

At this time we’ll take our next question which will be from Anthony Petrone with Jefferies Group.

Thanks and welcome, Steve. Maybe just a little bit more on your statement on sort of the slowing the declines in some of these businesses, they’ve been facing some headwinds pretty consistently here, some of them are certainly secular, you mentioned that the shift in ThinPrep testing and also some of your customers in diagnostics have been talking pretty steadily about utilization and pricing declines. So may be a little bit more on actually how you sort of reverse some of the trends we’ve been seeing pretty consistently for the past year or so and then just a follow-up on capital structure comments that you had?

Sure. Let me start on the trends and first and foremost it’s going to be about driving growth and accelerating further growth on the growth franchises. The second part was to your jack point of slowing the decline; I think we’ve got several things here. One is just sales force execution and by the way I’m talking about slowing these on the margin probably but things like even NovaSure or ThinPrep making sure that our reps aren’t just accepting the macro headwinds and make the extra call. Let’s still remind people why our products are superior to those in the competitive set and still try to get those extra sales. I think sometimes it could become a self-fulfilling prophecy when you got all the headwinds you just sort of throw up your hands. And I think by just shining it brighter light and a greater focus and remaining people that the way we grow is really a combination of not losing as much on one side so you’re just replenishing the other side. It’s a bit of accelerating the positives but trying to do what you can to hold on fight off the declines a little bit. Having said that let’s be clear. The ThinPrep, NovaSure, those are still legitimate headwinds, those will continue to decline, but if we can even slow the rate of decline from minus 10% to minus 9% or minus 8% on the margin those will be improvements and then eventually frankly I hate to say but anniversary-ing will start to help us a little bit as we go certainly into 2015 and beyond.

That’s helpful. And just on the capital structure, can you maybe walk through the strategy there for net pay downs in terms of prioritization. Should we expect pay downs on the higher interest portions of the cap structure or are there restrictive covenants that require your initial pay downs to be allocated toward the term loans?

Yes, Anthony, let me talk a little bit there. When we look at the pieces of the debt for a moment between the term loan A and B and then the senior note and then the convertible, we really have three pieces. The senior note, we don’t have an ability until 2015 to do anything with that and that is the highest interest rate. Our focus today is to try to lower the term loan B, because that’s the highest interest remaining of what’s left. The convert actually has a small coupon today. So that’s where our focus is. The B is also variable at the moment. So it would be the priority as we generate cash and pay down debt.

At this time, we will take a question from David Lewis with Morgan Stanley.

Good afternoon.

Hey, David.

Steve, how are you?

Great.

I wanted to come back to something you focused on the call here. Your return to growth was clearly the message on the call, but you also mentioned the need to invest in areas like the o-U.S. to drive that growth. So I do think a question that many holders have is can you return to growth without a return to increased spending? So does the EPS guidance give you the flexibility you need to accelerate growth and if it does, can you help us understand how you reallocate some of that spending to focus on the areas you think are best suited to accelerate that growth?

Sure. I think to be clear the current EPS guidance does give us that latitude. And we are already talking within the team as I see some pockets of strength as to some additional investments we could make even this year whether it’s sales or frankly R&D projects to kind of self-fund some additional growth and still deliver on the EPS line and really start to set ourselves up for the future. So I think overall as you well know, we have got a pretty good operating margin and we are going to have to increase I think some spending in R&D and probably sales force expansions, but I think we can find that money internally so that we don’t have the depressed margin to do it. As you also well know and I probably articulated, some of that is not going to affect our business in the next few quarters, but 2015 and beyond hopefully they start to at least see some of it. Internationally, the opportunities here are enormous. And I will tell you I saw some pockets – we saw some pockets of growth internationally that the total numbers kind of mask, but our core business is an example in Europe. All three franchises showed some reasonable and very good growth in Europe. So at a time when I think a lot of companies are challenged in Europe, I think we have got opportunities there and it will by shining a brighter light really allow us to invest further, but again without really seeing margin decline.

Okay, thanks Steve. Very helpful. And then next question just on gross margins, I think you talked about that gross margin trend fading across the quarters. I guess maybe give us a little more detail about that, it was a stronger GM that you saw in the year ago period, but it’s just not clear to me why that GM would fade so dramatically throughout the balance of the year given the strength here and considering the growth was so depressed here in the first quarter, you still had a very strong GM number. Help us understand specifically what drives that depression throughout the quarters?

Sure, David. So the gross margin percentage in Q1 was a bit more than 63%, which is the highest that we have posted in sometime. And it’s fair to say it is not one item, it’s a whole host of things that kind of clicked and found a place for us during the quarter. Some of it was a very nice product mix to the Breast Health side, an increase in service without any increase in service cost, so an enormous amount of gross margins from that. We were heavily weighted to the U.S. this quarter more so than other quarters. We are actually a little bit lower on the international side. So we have better price in the U.S. We did have some manufacturing variances that were positive. We had very good absorption, because our inventory was up for the quarter. I know it sounds like a laundry list, but it really is. We did have a slowdown in hiring and expenses in Q1. These are the things I expect not to fully reverse, but even out for the remainder of the year. So at this point in the year after only one quarter, we would be more comfortable with the current guidance that we have already provided the 61.5% to the 62%.

And David, I would add an overall comment too. I think one of the things I want to make sure we do is we establish our new reputation here is be very credible as we are going forward and not over celebrate something and having us think we are at a new level because obviously I think we have gotten into the – trying to point out the real positives in a quarter and neglecting some of the others. And I think we have heard from all of you credibility is key. You know that’s a very important mantra of mine. So I think this quarter was unusually good, we would love to celebrate. Hopefully, you know we are going to be working hard to improve upon even the guidance, but don’t want to get ahead ourselves at this stage in time.

At this time we will take the question from Rich Newitter with Leerink Partners. Please go ahead.

Hi, thanks for taking the questions and welcome to Hologic Steve.

Thank you, Rich.

Maybe I can just start with a little bit bigger picture. I appreciate and thank you for giving us the comments on 2015 and that there is likely a return to growth in store in that time period. Can you maybe give us a sense especially in light of the fact that you don’t see any dramatic strategic shifts in the businesses right now or restructuring of the businesses, what’s the long-term growth potential is of the assets you have in place?

You know what, I want to careful at this stage getting into long-term projections. I feel good, but I have got to get my sea legs a little bit further and I want to be careful not to get too far ahead of ourselves. Sorry about that.

That’s okay, that’s fair.

Our long-term right now is made out of starting to execute better quarter-over-quarter while we sorted out. But I do feel like franchises we are in should be nice growth drivers.

Okay. And just going back to your comment on reallocation of investment, specifically with respect to sales – I think you said reinvigorating the sales force and some of the businesses that you are seeing secular challenges, how do you view that, are there incentive structures you will put in place, what specific initiatives can we expect from the next few quarters?

Sure. Some of it’s as simple as really looking at the call calendars and making sure that while we are driving growth on one franchise we are not completely neglecting the others. It is setting up the quarters and frankly I think team has already done a pretty good job here of making sure that the sales reps quotas include multiple product lines aren’t just totals. So it’s just driving down to that kind of level of detail making sure we have got the right people in the right focus areas. And then the second part will be probably particularly outside the U.S. starting to look at where are there pockets that we might expand our sales organizations.

At this time we’ll take the question from Bill Quirk at Jefferies. Please go ahead.

Great, thanks, good afternoon. Steve first question and I realize it’s a bit of tricky one, but given the importance of Gen-Probe in your future plans, here is one of the three-pronged growth strategies, as well as just kind of considering the overall level of change that the organization has been through over the past year, can you talk a little bit about the morale of the organization and just help us think a little bit about retention there too? Thank you.

Bill, it’s a great question. I will answer to you exactly what I told our Board last week. I think when I arrived here there were a number of people, dare I say with one foot out the door. And I think with my arrival a whole bunch of them kind of stopped that foot out the door, stopped making phone calls out and are very intrigued. But some are – many and especially I think frankly out in San Diego are still waiting to believe. But they want to believe they have invested their heart and souls and that so many people at the grassroots level of this company have spent their lives really helping build it up and want this company to fulfill its rightful potential. And I think we really have a lot of them reengaged, reenergized as we are going forward. So we are not quite where I want to be as I told our Board I am not sure lot of these people are ready to run into the burning building behind me, but I think will be there here in the coming months. I am very encouraged by what I am seeing. But we do have work to do. You don’t go through that the amount of leadership turmoil that we went through both at the top of Hologic and also frankly at the Gen-Probe facility in San Diego in a 12 months period without having a meaningful and significant impact on morale. So – but I think we have bottomed and are on the way up now. But – and I do think that’s going to be a big driver of performance in the future. When you have people with one foot out the door 5 0’clock rolls around they are ready to head home. When they believe what they’re working in they’re giving you that extra effort, they’re making that extra sales call, they’re working that extra project and product development and that’s where we need to be.

Understood. And then just as a follow-up for Glenn, certainly good to hear about the overall Aptima performance; obviously understand that Quest had a hand to play there, can you speak a little bit too, I don’t know if organic is the right term to use here but kind of what the Aptima franchise look like without the benefit of Quest?

Organic is the right phrase, Quest is organic, so but no – I’m sorry that’s me being a wise guy. I’ll hand it over to Glenn.

Yes that was my answer too. Yes, Bill that’s a tough one. We really can’t comment and try to pull out what Quest contributed, but we’re very happy with the uptake I mean we talked about last quarter that Quest had ordered and had installed a large number of their new TIGRIS systems in the summer time. So this was the first quarter we begun to see some real benefit from Quest. The real pickup is on the Aptima CT/GC side. I think some of the new Aptima assays like Trichomonas more of a new test. We’ll be yet to see going forward as will be HPV. So there is a lot of ground for us to pickup with Quest. So we’re very happy with their initial push for the product, get into those TIGRIS is up and running.

But it is broader than Quest as well.

No doubt.

In terms of the growth.

Moving forward you’ll hear from Brian Weinstein with William Blair. Please go ahead.

Hi, thanks for taking the questions and good afternoon. Stephen, I was hoping to push you just a little bit more on the o-U.S. situation. It’s obviously only 25% or so of revenues. It’s been an area that people have talked about investments here for a while, and Gen-Probe has been an asset, that’s been notoriously underrepresented outside the U.S. So I’m just curious if you can be a little bit more specific on things you can do, are there specific products that you’re going to highlight o-U.S., are there specific territories, and can you give us an update on the Far East and China and what’s going on there? Thanks.

Sure. Great question. I think it does get down to a granular focus on how we start to build it by franchise and by country and it’s understanding the reimbursement environments in each of the major countries and what we can do to influence that. So if I would articulate a strategy here, this is clearly going to take time, but it does start with market access, do we have the right reimbursement for the right product lines in the right countries? And if you really dial it down I would tell you, I just don’t think we’ve been very focused there, we may have talked about it in the past but the results and there I’d say even the internal reports and Glenn and I had a lot of good discussions about it. The internal reporting system within the company to me is not been as focused on even looking at the international business within the months and within the quarters and I’m a big believer that what you measure allows you to ask the questions and drive it. So now to go one level further down in granularity, if I look the molecular diagnostics business, clearly as you mentioned it’s ballpark, it’s about 15% of our revenue is outside the U.S. There is no reason to be that low I mean that’s obviously from more of the Gen-Probe base, where the cytology piece of our business is probably more like 30% plus outside the U.S. If we think about the Breast Imaging business generally still probably three quarters of it is in the U.S. and then the GYN Surg business frankly is about almost 90% is in the U.S. So right now we’re literally going through – if you take Europe as an example country-by-country, franchise-by-franchise, okay. If…

Thank you very much.

At this time, we will go to Isaac Ro with Goldman Sachs.

Good afternoon guys. Thanks for taking the question.

Sure Isaac.

Hi, Steve. I just want to ask one on the overall volume environment, we have seen obviously some pretty good results not only from you guys, but other companies across MedTech and actually Abbott Labs (ph) this quarter. So I am wondering if you thought you saw any pull forward in volume in the calendar fourth quarter and trying to get a sense as a result what you guys are assuming for seasonality on a sequential basis as we move into first calendar quarter?

Sure. I don’t think we saw lot of pull forward from our customers be in the quarter. Typically, we do see a little bit of a downtick based on our set of businesses in the calendar first quarter, which is why our revenue guidance for this quarter kind of brackets roughly. Typically, we go down our revenue guidance actually has us probably flat sequentially, which maybe modest improvement in terms of growth rates or lack of declines, but I don’t think we really saw lot of pull forward from the quarter. Glenn, do you have anything to add there?

No. I think that sums up, Steve. We haven’t seen any pull-through in Q1 December and we don’t have a lot of seasonality built into our business anymore now that we have especially on a consolidated basis. When we look at the surgical business, we always have the reset of insurance deductibles that hit us in the March quarter, but that’s offset by other parts on the molecular side, the diagnostic side.

That’s helpful. And then just a follow-up on the comment you made on potential select divestitures, just wondering if you had an updated view on what kind of criteria you will place on those decisions? That will be helpful in framing your thoughts there. Thank you.

Sure. At the end of the day, we are obviously focusing on what we can do to grow our business. The three big franchises for the most part have very good growth drivers. There maybe some products in some of those areas that we might think may not necessarily be growth drivers that we may look at, very much on the smaller side of things.

At this time, we will move forward and take a question from Jayson Bedford of Raymond James.

Good evening. Thanks for taking the questions. Just wanted to circle back to gross margin and the strength in the quarter, you hinted that Breast Health was strong. Just wondering did you see a bigger impact from upgrades meaning those folks going from as I mentioned 2D to as I mentioned 3D and wondering if that had a positive impact on gross margin in the quarter?

No, that actually wasn’t it, Jayson. It was just more 3D in total. It wasn’t the upgrades. I mean, those are potentially opportunities that continue to be out there. When we think about 3D sales, there is still – the upgrade portion is still between 20% and 30%. There really wasn’t a shift to the upgrade, but every quarter, you are correct, we continue to sell 2D dimensions into the U.S. market and those all could be upgraded at some point in the future.

Okay. And just as a quick follow-up, what’s left in terms of converting your business with Quest?

Well, the TIGRIS units are in place at Quest today and it’s a matter of them adopting all the molecular assays. So the first to adopt was on the CT/GC side. We are expecting ramp ups over time of both Trichomonas as they move to NAT testing for Trich and then also on the HPV side. I – we will also say that the arrangement with Quest does expand hopefully our use of ThinPrep as well. They were a company that used both ThinPrep and SurePath. So we would have the expectation of some increases on the ThinPrep as well, so we are early on in all those pieces right now Jason.

Okay, thank you.

At this time, we will take the question from Jon Block with Stifel.

Great. Thanks and good afternoon. Maybe the first one just to focus on G&A for a second, it looks like it was a big increase in G&A and maybe if you can just be a little bit more specific where that went in the quarter, was that towards building some of the long-term international infrastructure Steve that you referenced or was it geared more towards augmenting the sales force with some domestic opportunities? Thanks.

It was less around the long-term than I would clearly like to say. Glenn do…

No, Jonathan it’s kind of no to those questions. The G&A went up because number one we have the med device tax year-over-year in there, but also in the December quarter we are heavily weighted with our SG&A expenses and all our national tradeshows. So this Q1 is our expensive quarter in total. In addition, those expenses include a number of stock options and equity type expenses. We had some leadership changes those thing don’t come cheap, so some of that is included in the G&A as well.

Well, good. That was Glenn’s right way of saying that the hiring of me drove our SG&A up a little bit, but we are going to make up for that, don’t worry.

Steve, please don’t mind, but I meant it to be high value though, however, you did take that right, Jonathan.

Absolutely, understood. And then maybe this is a follow-up, Steve you have mentioned I think referred to some additional offerings in the GYN segment and is that something you can see in internal R&D or are there opportunities sort of in the more immediate term from possible call tuck-in acquisitions? Thanks.

Sure. I think it will be a bit of both, clearly I think just by starting to talk again and not just talk and people are seeing it as really focusing on organic growth. We have got that group as an example. One that was feeling like a little bit of redheaded stepchild I think in a big company for a bit being reenergized, I love that business it’s one I am comfortable with. And to me it’s all about constant innovation, upgrades to your existing products and starting to talk with that team about that. And also giving them license to say hey, folks this maybe one where if you find a small product line tuck-in acquisition. Even something with $10 million or $15 million for that business would be very meaningful that then we can grow those things over time. So I think empowering them to start to look both internally and externally is the focal point. So again, nothing that’s going affect the trajectory next quarter, but that mindset I think really will start to pay dividends here and hopefully 2015 and beyond.

Great, thank you.

At this time, we will move to Vijay Kumar with ISI Group.

Thanks guys. So maybe my first question for Steve, I just wanted to ask you about, has there been any major surprises either for the upside or the downside since you are down the role of CEO, what’s been – what’s sort of – what’s been the focus for you as you can sort of get your arms around the business?

Sure. I think the upside is probably that our sales teams and some of our sales leaders, there has probably been a few more changes there over the last year or two to the positive. I frankly thought the organization might be slightly sleepier given the market share positions, but I think there is actually some very good strength there which gives me the latitude as we do some shifting around the organization the priorities to I think really help drive it forward. I think that, so yes hopefully that answered it.

Got it. And maybe one for Glenn, would you be willing to comment what proportion of your GYN Surgical businesses might show right now and what was the decline in 2D mammography business? Thanks.

Yes, let me think about how best to answer that, Vijay. We – on the GYN Surgical side in the 10-Q coming out in a couple of days we’ll talk about the MyoSure increase and it will talk about at $5 million increase in MyoSure. So that’s – that’s a nice double-digit growth. When we think about MyoSure itself the 10-Q also talked about a NovaSure decrease of about $7 million. So that’s a slight single, low single digit kind of decline. What we’re looking for is for that to level off in the NovaSure side, we are encouraged on the international side, we have gotten some approvals that we haven’t had in prior years. So we’re at a point we think where the MyoSure growth will begin to overtake any kind of NovaSure decline, we’re pretty close to that. On the 2D I don’t know if we talked about specifics on the 2D decline, but this is what we’ve been waiting for I mean at some point the 2D goes to zero, right, I mean we are expecting everything in the future to be 3D that is the way the market should move, tomo should become the product out there because of how clinically sub-carrier it is today. If we think about dimensions because I know I commented on dimensions before the new product line. Dimensions are about 80% of that total digital mammography product line item.

At this time, we’ll take a question from Doug Schenkel with Cowen and Company.

Hi, good afternoon. One would think pricing has to be under pressure due to broader challenges in the diagnostic and healthcare space and specifically due to the impact of the Quest agreement I guess treating that as organic using the logic you applied in response to an earlier question, could you provide data on pricing volume trends specifically within the diagnostic segment and then also more broadly across the Company?

Yes let’s think about that for a moment. I think it’s hard to be general about diagnostics so Doug. And I think we all understand what’s going on with ThinPrep. Here in the U.S. that is volume, volumes have dropped on the ThinPrep side. We’re looking to soften that decline over the next year. So international it is true that ThinPrep, the ASPs have dropped a bit as well, part of that is intentional on our part especially in Asia as we’ve moved more to some dealer type arrangements away from direct for a whole host of reasons. On the diagnostic side, we do see more lab consolidation; so that is going to have a slight impact on ASPs. I think in general though we are seeing volumes increase as we win more account, more account closures, many of those are competitive but many of the competitive wins do come with a bit lower ASPs at the trend that we would expect to go forward but it is also part of the future strategy as PANTHERs get placed into the field, it really does provide us with that platform for the future I mean and this is really key to what we’re trying to do. We’re talking about particularly assays today that a lab they only have on or two of our assays that PANTHER goes in they set running CT/NG, next thing they are running as HPV, they don’t yet have Trichomonas, Trichomonas begins to be a bigger part of the market. So this is all trying to place from our perspective as many PANTHERs as we can. And as Steve said this was our best PANTHER placement quarter. I would expect it go up next quarter. We’re seeing very great uptake on PANTHER itself and I think it is an automation that will really set us apart in the market today and I think for the first time we have a full set of assays that we can take advantage of. So hopefully some of that shift as we go forward.

So that’s helpful. I guess with that in mind maybe two quick very related follow-ups. The first is given everything you just described Glenn is that part of the explanation for why you would expect the gross margin comes under pressure a bit more moving forward?

Well I was really trying to comment on the remainder of FY ‘14 though Doug. And we have to remember for FY ‘14 we’re not guiding to any revenue overall consolidated revenue increase. So I would expect this pretty – this range of 61%, 62%. As we look into FY ‘15 I think it changes. I think there will be the ability for us to drive additional margin both at the gross margin and the operating margin level as our revenues begin to tick up in part because of these new placements of PANTHERs. So I think FY ‘14 is more about it being a flat revenue year than it is anything else.

We will as we go forward though I would say outside the U.S. as we start to grow that business outside the U.S. that will probably come at some lower margins. So I wouldn’t model lot of margin – gross margin expansion, because we will have, to your point, Doug, there will be some pricing pressure in the U.S. and as we go outside the U.S., there maybe some slightly lower selling prices, but the key will be to growing the top line fast enough to be able to keep the overall margins in good shape.

At this time, we will take one more question for the day. This will be from Bill Bonello with Craig-Hallum.

Hey, great. Thanks a lot for taking my questions. Just a couple of follow-ups on the women’s health business, you talked a lot about the traction that you are getting currently with PANTHER, which sounds positive. I guess my question is you didn’t talk much about sort of the future with the women’s health business and what you are doing to drive sort of increased growth across the installed base or what you will be doing and sort of what you may need to do to remain competitive as other companies, whether it’s Cepheid or Roche sort of continue to introduce new assays and new instruments? And then I have a follow-up on profitability.

Sure. We are clearly very well invested in pipeline developments on additional women’s health assays, a scenario that obviously is the near and dear to our heart over time and will continue to be a very strong level of core competence. It’s also an area where I tell you when you combine the physician sales force that we have along with the lab sales force, I think it’s an area that really we should continue to be able to drive some good growth despite the competitive position there.

Okay. And then just in terms of profitability, is there anything that you can do with the ThinPrep business given that sort of the structural decline in volumes that’s happening and the potential that, that might continue? Is there anything you can do to sort of right-size that business? Do you have any pricing power at all? Just thoughts on how you might make that business more profitable?

Yes. I would tell you, it’s actually very profitable today and it’s frankly helping spin off a lot of profitability to invest in other parts of the business. Like any businesses in decline, we will always be looking to do we have the right resource allocation and everything else on it, but again, kind of like we said earlier, you want to be careful, you don’t pull resources away from it too much. It’s a remarkably great franchise. And some of the questions we are asking ourselves are, are there other ways we can breathe new life into that ThinPrep vial was an example. So we will certainly be seeking both maximized profit on that, but also figuring out how to either stop the declines or even figure out the ways to turn it back to a growth business over time and on a global basis. Thank you.

That does conclude the question-and-answer session and this does conclude today’s conference call. Thank you all for your participation. You may now disconnect.